Nhs England Drugs List v13

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND
VERSION 13 PUBLISHED APRIL 2018
SUITABLE FOR
SUITABLE FOR
SHARED CARE
SPECIALIST SHARED CARE
BETWEEN
PRIOR CENTRE ONLY WITH PRIMARY
SPECIALIST
MONITORING/AUDIT APPROVAL (includng outreach CARE (IF
DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA AND
REQUIREMENTS PROFORMA when delivered as SUPPORTED BY
SECONDARY
REQUIRED part of a provider LOCAL
CARE VIA
network) PRESCRIBING
NETWORK
COMMITTEE)
MODEL
HIV IN COMBINATION WITH OTHER ANTI-
ABACAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NHS ENGLAND CLINICAL
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
ABACAVIR + LAMIVUDINE + RETROVIRAL DRUGS
DOLUTEGRAVIR (TRIUMEQ®) B06/P/b/AGREED REGIONAL GUIDELINES
ABACAVIR + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ABALOPARATIDE DRUGS AFFECTING BONE
MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
ABATACEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
PAEDIATRIC INDICATIONS (WHERE
ABATACEPT NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA'S (TA195, TA280) NICE NICE NICE √
ADULT TA AVAILABLE)
TA259, 387 (SEE ALSO SSC1438)
NICE/NHS ENGLAND POLICY NICE
ABIRATERONE CANCER NHS ENGLAND HORMONE ANTAGONISTS ONLY IN ENZALUTAMIDE NAÏVE SACT √ √
PATIENTS
ADALIMUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
ADALIMUMAB UVEITIS - ADULTS NHS ENGLAND CYTOKINE MODULATORS TA460 NICE NICE NICE AUDIT √ √
HIGHLY SPECIALISED HIGHLY SPECIALISED

ADALIMUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √
CRITERIA ONLY CRITERIA ONLY
AS PER TA455 OR ADULT TA'S (TA130,
PAEDIATRIC INDICATIONS (OR WHERE
ADALIMUMAB NHS ENGLAND CYTOKINE MODULATORS TA143, TA146, TA187, TA199, TA329, NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE)
TA392, TA460)
ADALIMUMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS NICE TA 392 NICE NICE NICE AUDIT √ √
VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED
ADEFOVIR HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS (CG165)
AFATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA310 NICE NICE SACT √
NOT ROUTINELY COMMISSIONED
AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ √
(TA307)
DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED
AGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DISORDERS CRITERIA ONLY CRITERIA ONLY
AGALSIDASE BETA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
ALBUTREPENONACOG ALFA HAEMOPHILIA B
NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √
ALBUTROPIN ADULT ONSET GROWTH HORMONE
GROWTH HORMONE & GROWTH
DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HORMONE RECEPTOR ANTAGONIST
ALDESLEUKIN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
DRUGS AFFECTING THE IMMUNE
ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLAND TA312 NICE NICE NICE AUDIT √ √****
RESPONSE
TRUST GUIDELINES: ISLET
PRE-TRANSPLANT DRUGS AFFECTING THE IMMUNE
ALEMTUZUMAB NHS ENGLAND TRANSPLANTATION (ONLY IF PROVIDED TRUST GUIDELINES TRUST GUIDELINES √
IMMUNOSUPPRESSION RESPONSE
AT ZERO DRUG COST)
DRUGS AFFECTING THE IMMUNE TRUST GUIDELINES: (ONLY IF
ALEMTUZUMAB CLL NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES SACT √
RESPONSE PROVIDED AT ZERO DRUG COST)
HIGHLY SPECIALISED CRITERIA ONLY
ALEMTUZUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS (ONLY IF PROVIDED AT ZERO DRUG HIGHLY SPECIALISED CRITERIA √
COST)
ALGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DRUGS USED IN METABOLIC
ALIPOGENE TIPARVOVEC LIPOPROTEIN LIPASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
VIRAL HEPATITIS (B&C) &
ALISPORIVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS
ALPHA MANNOSIDASE DRUGS USED IN METABOLIC
ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RECOMBINANT HUMAN DISORDERS
VASODILATOR ANTIHYPERTENSIVE
PULMONARY ARTERIAL NHS ENGLAND CLINICAL
AMBRISENTAN NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION COMMISSIONING POLICY: A11/P/c
HYPERTENSION
AMIFAMPRIDINE PHOSPHATE LEMS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY: 16009/P
AMIKACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CYSTIC FIBROSIS
AMIKACIN LIPOSOMAL NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NUMBER OF PATIENTS TREATED

AMPHOTERICIN LIPOSOMAL FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS WITHIN POLICY
ANAKINRA JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: E03/P/d
SPECIALIST AUTOINFLAMMATORY
ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISEASE
ANAKINRA PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CRYOPYRIN ASSOCIATED PERIODIC CRYOPYRIN ASSOCIATED PERIODIC HIGHLY SPECIALISED HIGHLY SPECIALISED
ANAKINRA NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED DATABASE √
SYNDROME SYNDROME SERVICE SPECIFICATION CRITERIA ONLY CRITERIA ONLY
ANIDULAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
ANTIHAEMOPHILIC FACTOR/VON AS PER BCSH GUIDELINES FOR
NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
WILLEBRAND FACTOR COMPLEX SPECIALISED INDICATIONS
NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 1 23/03/2018

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,

ANTILYMPHOCYTE GLOBULIN NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS
ANTIPSEUDOMONAS AERUGINOSA
CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IgY
AS PER BCSH GUIDELINES FOR
ANTITHROMBIN III NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
SPECIALISED INDICATIONS
ANTITHYMOCYTE APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,
NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
IMMUNOGLOBULIN ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS
APREMILAST PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CLINICAL GUIDELINES FOR
INTRAVENOUS/SUBCUTANEOUS
ARAGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN NORMAL IMMUNOGLOBULINS
EDITION UPDATE (JULY 2011)
ASFOTASE ALFA HYPOPHOSPHATASIA NHS ENGLAND HST6 NICE NICE AS PER MAA √ √
DISORDERS
ASUNAPREVIR + DACLATASVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ATACICEPT SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
ATALUREN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NICE HST3 NICE NICE NORTHSTAR DATABASE √ √

ATAZANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ATAZANAVIR + COBICISTAT HIV IN COMBINATION WITH OTHER ANTI-
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
(EVOTAZ®) RETROVIRAL DRUGS
AVORALSTAT HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
AXITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA333 (also refer to circular SSC1508) NICE NICE SACT √
AZACITIDINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME TA218 NICE NICE SACT √
NHS ENGLAND CLINCAL
AZTREONAM LYSINE CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
COMMISSIONING POLICY: A01/P/b
CYSTIC FIBROSIS (CONTIUOUS
AZTREONAM LYSINE NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND CLINCAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREATMENT)
COMMISSIONING POLICY: 16001/P
BARICITINIB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
CORTICOSTEROIDS AND OTHER
BASILIXIMAB RENAL TRANSPLANT NHS ENGLAND TA85 & TA99 NICE NICE √
IMMUNOSUPPRESSANTS
BECLABUVIR HEPATITIS C VIRAL HEPATITIS (B&C) &
NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BEDAQUILINE EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: F04/P/a
BEDAQUILINE MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
MALIGNANT DISEASE AND
BEGELOMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IMMUNOSUPPRESSION
DRUGS AFFECTING THE IMMUNE NOT ROUTINELY COMMISSIONED - NICE
BELATACEPT RENAL TRANSPLANT NHS ENGLAND NICE TA IN PROGRESS NICE TA IN PROGRESS NICE TA IN PROGRESS √
RESPONSE TA IN PROGRESS
BELIMUMAB SLE NHS ENGLAND NICE TA 397 NICE NICE NICE AUDIT √ √
RESPONSE
BENRALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BERACTANT RESPIRATORY DISTRESS SYNDROME NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

BETAINE HOMOCYSTINURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
BEVACIZUMAB CANCER CDF ANTINEOPLASTIC DRUGS CDF POLICY CDF CDF SACT √
AS PER NATIONAL PROTOCOL (SEE NF2 AS PER NATIONAL AS PER NATIONAL
BEVACIZUMAB NEUROFIBROMATOSIS NHS ENGLAND ANTINEOPLASTIC DRUGS AS PER NATIONAL PROTOCOL √
SERVICE SPEC) PROTOCOL PROTOCOL
BIMAGRUMAB INCLUSION BODY MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BIOTIN MULTIPLE SCLEROSIS NHS ENGLAND VITAMINS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYSTEMIC LUPUS ERYTHEMATOSUS
BLISIBIMOD NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(SLE)
BOCEPREVIR HEPATITIS C NHS ENGLAND TA253 NICE NICE HEPATITIS C MDS √ √
ORGAN REJECTION POST KIDNEY
BORTEZOMIB NHS ENGLAND ANTINEOPLASTIC DRUGS (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRANSPLANT
COMMISSIONING POLICY: A07/P/c)
NHS ENGLAND/ TA129, TA228, TA311, TA 378 NICE NICE
BORTEZOMIB CANCER ANTINEOPLASTIC DRUGS SACT √
CDF CDF POLICY CDF CDF
BOSENTAN DIGITAL ULCERS NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
HYPERTENSION
BOSENTAN NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
BOSUTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 401 NICE NICE SACT √
TORSION DYSTONIAS AND OTHER
BOTULINUM TOXIN FOCAL SPASTICITY IN CHILDREN NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
INVOLUNTARY MOVEMENTS
INTRAVESICAL USE IN SPINAL CORD TORSION DYSTONIAS AND OTHER
BOTULINUM TOXIN**** NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √
INJURY INVOLUNTARY MOVEMENTS
BRINCIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
BRODALIMUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT COMMISSIONING POLICY: B09/P/b
HEREDITARY ANGIOEDEMA - NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P
HEREDITARY ANGIOEDEMA -
AS PER NHS ENGLAND CLINICAL
C1 ESTERASE INHIBITORS PROPHYLACTIC TREATMENT IN NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
CHILDREN (CINRYZE ONLY)
CRYOPYRIN ASSOCIATED PERIODIC CRYOPYRIN ASSOCIATED PERIODIC HIGHLY SPECIALISED HIGHLY SPECIALISED
CANAKINUMAB NHS ENGLAND IMMUNOMODULATING DRUGS HIGHLY SPECIALISED DATABASE √
SYNDROME SYNDROME SERVICE SPECIFICATION CRITERIA ONLY CRITERIA ONLY

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
CANAKINUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND IMMUNOMODULATING DRUGS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(TA302)
CARGLUMIC ACID UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
CARNITINE CARNITINE DEFICIENCY NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
CASPOFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
CONGENITAL FACTOR XIII A-SUBUNIT

CATRIDECACOG NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DEFICIENCY
CERALIFIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LYSOSOMAL STORAGE DISORDER
CERLIPONASE ALFA NEURONAL CEROID LIPOFUSCINOSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
CERTOLIZUMAB PEGOL PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CETUXIMAB CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA145, TA176, TA439, TA473 NICE NICE SACT √ √
CEREBROTENDINOUS DRUGS USED IN METABOLIC
CHENODEOXYCHOLIC ACID NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
XANTHOMATOSIS (CTX) DISORDERS
CHENODEOXYCHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
INBORN ERRORS IN PRIMARY BILE DRUGS USED IN METABOLIC
CHOLIC ACID NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ACID SYNTHESIS DISORDERS
CIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
CIPROFLOXACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CIPROFLOXACIN LIPOSOMAL CYSTIC FIBROSIS
NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(INHALED)
CLADRIBINE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA492 NICE NICE NICE AUDIT √ √****
PULMONARY LANGERHANS
CLADRIBINE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HISTIOCYTOSIS
COBICISTAT NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
F03/P/b/AGREED REGIONAL GUIDELINES
PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE
COBITOLIMOD NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE) RESPONSE
CO-CARELDOPA INTESTINAL GEL PARKINSON'S DISEASE NHS ENGLAND NEURODEGENERATIVE CONDITIONS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: D04/P/e
NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
COLISTIMETHATE SODIUM CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √*
NICE NICE NICE AUDIT
TA276
CONESTAT ALFA NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT ONLY COMMISSIONING POLICY: B09/P/b
CRIZOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 406, 422 NICE NICE SACT √
CYSTEAMINE (MERCAPTAMINE) NEPHROPATHIC CYSTINOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DABRAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA321, 396 NICE NICE SACT √ (TA396) √
DACLATASIVIR HEPATITIS C NHS ENGLAND TA 364 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA441 NICE NICE NICE AUDIT √ √
DARUNAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DARUNAVIR + HIV IN COMBINATION WITH OTHER ANTI-
COBICISTAT (REZOLSTA®) RETROVIRAL DRUGS
DASABUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND/ NICE TA 425, 426 NICE NICE
DASATINIB CANCER PROTEIN KINASE INHIBITORS SACT √
DECITABINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
(TA270)
DRUGS USED IN HYPOPLASTIC,
IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL
DEFERASIROX NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY
IRON OVERLOAD
DEFERIPRONE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
IRON OVERLOAD
DEFIBROTIDE HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
COMMISSIONING POLICY: B04/P/c
DELAMANID EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
DELAMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
DESFERRIOXAMINE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √
IRON OVERLOAD
DEXRAZOXANE ANTHRACYCLINE EXTRAVASATION NHS ENGLAND IMMUNOMODULATING DRUGS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
DEXRAZOXANE ANTHRACYCLINE CARDIOTOXICITY NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DIBOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NHS ENGLAND POLICY NHS ENGLAND POLICY AUDIT, BSR REGISTRY √
COMMISSIONING POLICY 16063/P
DIDANOSINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
DIMETHYL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA320 NICE NICE NICE AUDIT √ √****

DOLUTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
B06/P/b/AGREED REGIONAL GUIDELINES

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
HIV iN COMBINATION WITH OTHER ANTI-
DORAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
DORNASE ALFA PRIMARY CILIARY DYSKINESIA NHS ENGLAND MUCOLYTICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY 16029/P
DORNASE ALFA CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √*
DRISAPERSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DUPILUMAB ASTHMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
HEREDITARY ANGIOEDEMA - ACUTE
ECALLANTIDE NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TREATMENT ONLY
ORGAN REJECTION POST KIDNEY PAROXYSMAL NOCTURNAL NOT ROUTINELY COMMISSIONED
ECULIZUMAB NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRANSPLANT HAEMOGLOBINURIA NHS ENGLAND POLICY: A07/P/b
C3 GLOMERULOPATHY (POST PAROXYSMAL NOCTURNAL NHS ENGLAND CLINICAL
ECULIZUMAB NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TRANSPLANT) HAEMOGLOBINURIA COMMISSIONING POLICY: 16054/P

PAROXYSMAL NOCTURNAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY
ECULIZUMAB AHUS NHS ENGLAND COMMISSIONING POLICY: E03/PS(HSS)/A √
HAEMOGLOBINURIA NICE NICE NICE
NICE HST1
NHS NATIONAL SPECIALISED

PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL
ECULIZUMAB NHS ENGLAND COMMISSIONING TEAM SERVICE NSCT SERVICE SPEC NSCT SERVICE SPEC NSCT SERVICE SPEC √
HAEMOGLOBINURIA HAEMOGLOBINURIA
SPECIFICATION
EDRATIDE SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
EFAVIRENZ NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EFRALOCTOCOG ALFA /
EFMOROCTOCOG ALFA / FACTOR HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652, see also SSC 1818 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √
VIII FC FUSION PROTEIN (Elocta®)
EFTRENONACOG ALFA (Alprolix®) HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √

ELBASVIR HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
ELIGLUSTAT GAUCHER'S DISEASE NHS ENGLAND HST5 NICE NICE HIGHLY SPECIALISED DATABASE √
DISORDERS
LYSOSOMAL STORAGE DISORDER MANAGED ACCESS MANAGED ACCESS
ELOSULFASE ALFA MUCOPOLYSACCHARIDOSIS IV TYPE A NHS ENGLAND NICE HST2 MANAGED ACCESS AGREEMENT √ √
DRUGS AGREEMENT AGREEMENT
ELTROMBOPAG ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 293 NICE NICE NICE AUDIT √ √
ELVITEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
ELVUCITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
NON-ALCOHOLIC STEATOHEPATITIS DRUGS USED IN METABOLIC
EMRICASAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
(NASH) FIBROSIS DISORDERS
EMTRICITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE +TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE + TENOFOVIR HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
ALAFENAMIDE DESCOVY® RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
EMTRICITABINE + RILPIVIRINE +
HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL
TENOFOVIR ALAFENAMIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P
(ODEFSEY®)
ENFUVIRTIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ENTECAVIR HEPATITIS B NHS ENGLAND TA153 & IN PROGRESS NICE NICE NICE AUDIT √
TA316, TA 377 (SEE ALSO SSC1439)
NICE/NHS ENGLAND POLICY NICE
ENZALUTAMIDE CANCER NHS ENGLAND HORMONE ANTAGONISTS BOTH: ONLY IN ABIRATERONE NAÏVE SACT √
PATIENTS
EPOPROSTENOL (5) NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
EPRATUZUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPRODISATE AMYLOIDOSIS NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EPTOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA162, TA227, TA 374& IN PROGRESS
ERLOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE NICE SACT √
NHSE LETTER
ETANERCEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
PAEDIATRIC INDICATIONS OR (WHERE AS PER TA455 OR ADULT TA'S (TA103,
ETANERCEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE) TA130, TA143, TA199)
ETEPLIRSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

ETRAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ETROLIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
EVEROLIMUS (AFINITOR®) CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA421, TA432, TA449, TA498 NICE NICE SACT √ √
PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED
EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LIVER TRANSPLANTATION (TA348)
PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED NHS
EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HEART TRANSPLANTATION ENGLAND POLICY 16016/P
SUBEPENDYMAL GIANT CELL
EVEROLIMUS (VOTUBIA®) ASTROCYTOMA (SEGA) ASSOCIATED NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
WITH TUBULAR SCLEROSIS
RENAL ANGIOMYOLIPOMA NHS ENGLAND CLINICAL
EVEROLIMUS (VOTUBIA®) ASSOCIATED WITH TUBULAR NHS ENGLAND PROTEIN KINASE INHIBITORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
SCLEROSIS B14X09L

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
AS NICE TA 394
HOMOZYGOUS FAMILIAL
EVOLOCUMAB NHS ENGLAND LIPID-REGULATING DRUGS (FOLLOW GUIDANCE FOR NICE NICE NICE AUDIT √
HYPERCHOLESTEROLAEMIA
HETEROZYGOUS FH)
TREATMENT OF ADULT PATIENTS WITH

EX-VIVO EXPANDED AUTOLOGOUS MODERATE TO SEVERE LIMBAL STEM
HUMAN CORNEAL EPITHELIAL CELL DEFICIENCY (LSCD), UNILATERAL NHS ENGLAND ATMP TA 467 NICE NICE NICE AUDIT √ √
CELLS CONTAINING STEM CELLS OR BILATERAL, DUE TO PHYSICAL OR
CHEMICAL OCULAR BURNS

FACTOR IX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
FACTOR VIIA NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES, see also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR VIII INHIBITOR BYPASSING AS PER BCSH GUIDELINES FOR
NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FACTOR (FEIBA) SPECIALISED INDICATIONS
FACTOR XIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
FAMPRIDINE MULTIPLE SCLEROSIS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
NHS ENGLAND POLICY: 16010/P
FIBRINOGEN NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
FIBROBLAST GROWTH FACTOR 1
SOMATOSTATIN ANALOGUE NHS ENGLAND SOMATOSTATIN ANALOGUES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GENE THERAPY
FILGOTINIB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FILGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY √
PROPORTION GIVEN FOR SPC
FILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES TRUST GUIDELINES INDICATIONS WITHIN POLICY √
PRODUCT WITH LOWEST
ACQUISITION COST TO BE USED
FILIBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA254
FINGOLIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
NHS ENGLAND POLICY: D04/P/b
ANAEMIAS AND SOME OTHER BLOOD
FITUSIRAN HAEMOPHILIA A AND B NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
FLEBOGAMMA AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
FLEBOGAMMADIF AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
FORIGERIMOD ACETATE SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
FOSAMPRENAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
FOSCARNET CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
FOSTEMSAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
GALSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
GAMMAGARD AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
GAMMANORM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
GAMMAPLEX AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
GAMUNEX AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
GANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
GANETESPIB CANCER NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √
RESPONSE
GEFITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA192 NICE NICE SACT √
GEVOKIZUMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GLATIRAMER MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA32 & NHS ENGLAND POLICY: D04/P/b NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****

GLECAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
METHOTREXATE INDUCED RENAL NHS ENGLAND CLINICAL
GLUCARPIDASE NHS ENGLAND POISONING NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DYSFUNCTION COMMISSIONING POLICY: B15/P/a
GLYCEROL PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
GLYCOPEGYLATED FACTOR IX HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GOLIMUMAB PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS AS PER ADULTS TA'S (TA220, TA233) NICE NICE NICE AUDIT √
GRANULOCYTE-MACROPHAGE
ANTIBODY-POSITIVE PULMONARY
COLONY-STIMULATING FACTOR NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ALVEOLAR PROTEINOSIS
(LEUKINE® - IMPORT)
GRAZOPREVIR VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
HIV VACCINE HIV INFECTION PROPHYLAXIS NHS ENGLAND VACCINES AND ANTISERA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
HIZENTRA AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
HUMAN (HAEM) ARGINATE HEPATIC PORPHYRIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
HUMAN HETEROLOGOUS LIVER DRUGS USED IN METABOLIC
UREA CYCLE DISORDERS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CELLS DISORDERS
HUMAN PARATHYROID HORMONE- MALE AND JUVENILE OSTEOPOROSIS DRUGS AFFECTING BONE
RELATED PROTEIN ANALOGUE HYPOPARATHYROIDISM METABOLISM
HYQVIA AS PER NATIONAL DMP NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IBALIZUMAB NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RETROVIRAL DRUGS
ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
TREATMENT ONLY COMMISSIONING POLICY: B09/P/b
HEREDUTARY ANGIOEDEMA - NHS ENGLAND CLINICAL
ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √
PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P
IDEBENONE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

IDURSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
ILOPROST (5) NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
IMATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA70, TA86, TA251, TA326 NICE NICE SACT √
CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL

IMATINIB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
DISEASE COMMISSIONING POLICY:16069/P
IMIGLUCERASE GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
INDINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
INFLIXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
(NHS ENGLAND CLINICAL
INFLIXIMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
COMMISSIONING POLICY: D12/P/a &
D12/P/a)
AS PER ADULT TA'S (TA130, TA134,
INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS TA140, TA143, TA163, TA187, TA199, NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE)
TA329)
CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED -
INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INTERSTITAL LUNG DISEASE POLICY IN PROGRESS
INFLIXIMAB CROHN'S DISEASE IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA187 NICE NICE NICE AUDIT √
INFLIXIMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB RENAL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INFLIXIMAB SARCOIDOSIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NOT ROUTINELY COMMISSIONED - NHS
INFLIXIMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENGLAND POLICY 16018/P
INFLIXIMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √
INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND IMMUNOMODULATING DRUGS TA75 NICE NICE NICE AUDIT √
TA32
INTERFERON BETA MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****
INTRATECT AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
FUNGAL INFECTION (LICENSED
ISAVUCONAZOLE NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
INDICATIONS)
IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/c, NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
16049/P
IXAZOMIB AMYLOIDOSIS NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
IXAZOMIB MULTIPLE MYELOMA CDF CANCER EXCLUSION CDF (TA 505) CDF CDF SACT √ √
KIOVIG AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
LAMIVUDINE HEPATITIS B NHS ENGLAND CG165 NICE NICE NICE AUDIT √
LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
PRODUCT WITH LOWEST
LANREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
PROCUREMENT COST TO BE USED
LANREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √
PRODUCT WITH LOWEST
LANREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ √
LAPATINIB CANCER CDF PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED CDIFR CDIFR SACT √
LAQUINIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √****
LARONIDASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
LEBRIKIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND/ TA171, TA322 NICE NICE
LENALIDOMIDE CANCER IMMUNOMODULATING DRUGS SACT √
LENALIDOMIDE POEMS NHS ENGLAND IMMUNOMODULATING DRUGS HIGHLY SPECIALISED CRITERIA ONLY √

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
PROPORTION GIVEN FOR SPC
LENOGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES TRUST GUIDELINES INDICATIONS WITHIN POLICY √
PRODUCT WITH LOWEST
ACQUISITION COST TO BE USED
LENOGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY √
LETERMOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LEVOFLOXACIN (INHALED) CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NOT ROUTINELY COMMISSIONED -
LIPEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
POLICY IN PROGRESS
HYPONATRAEMIA AND OTHER POSTERIOR PITUITARY HORMONES
LIXIVAPTAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ENDOCRINE USES AND ANTAGONISTS
HOMOZYGOUS FAMILIAL
LOMITAPIDE NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERCHOLESTEROLEMIA
LONAFARNIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
LOPINAVIR + RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
LUMACAFTOR AND IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA IN PROGRESS
MACIMORELIN GROWTH FAILURE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MACITENTAN NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION
MANNITOL CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/b √
TA266
MARAVIROC NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
MASITINIB PANCREATIC CANCER/GIST NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MAVRILIMUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
GROWTH HORMONE & GROWTH NHS ENGLAND CLINICAL
MECASERMIN GROWTH FAILURE NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HORMONE RECEPTOR ANTAGONIST COMMISSIONING POLICY: EO3/P/a
TA431
MEPOLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE NICE NICE AUDIT √ √
METRELEPTIN DYSLIPIDAEMIA NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MICAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
MIGALASTAT FABRY'S DISEASE NHS ENGLAND NICE HST4 NICE NICE HIGHLY SPECIALISED DATABASE √
DISORDERS
MIGLUSTAT GAUCHER'S DISEASE/ NIEMANN-PICK NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
MOMELOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
MOTAVIZUMAB RSV PROPHYLAXIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA127
NATALIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
NELFINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NEVIRAPINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
NILOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA241, TA251 NICE NICE SACT √
NINTEDANIB OVARIAN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED CDIFR CDIFR SACT √
NINTEDANIB (OFEV®) IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA 379 NICE NICE NICE AUDIT √ √
NINTEDANIB (VARGATEF®) NON-SMALL-CELL LUNG CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA347 NICE NICE SACT √
NITAZOXANIDE HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NITISINONE ALKAPTONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
NITISINONE TYROSINAEMIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
PULMONARY ARTERIAL
NITRIC OXIDE NHS ENGLAND DRUGS/PULMANORY ARTERIAL AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
HYPERTENSION
HYPERTENSION
NONACOG ALPHA (BeneFIX) HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √
NONACOG BETA PEGOL HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NORMAL IMMUNOGLOBULIN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
OBETICHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND TA443 NICE NICE NICE AUDIT √ √
DISORDERS
OCRELIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPONSE
OCTAGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
OCTOCOG ALFA HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

OCTREOLIN ACROMEGALY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PRODUCT WITH LOWEST

OCTREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
OCTREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √
PRODUCT WITH LOWEST
OCTREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
OFATUMUMAB CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA344 NICE NICE SACT √
OFATUMUMAB PEMPHIGUS VULGARIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OLESOXIME SPINAL MUSCULAR ATROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OMALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA278 NICE NICE NICE AUDIT √ √
OMBITASVIR/PARITAPREVIR/RITON VIRAL HEPATITIS (B&C) &
AVIR + DASABUVIR + RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS
OSILODROSTAT CUSHING'S DISEASE NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
OZANIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PACRITINIB MYELOFIBROSIS NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
VIRAL HEPATITIS (B&C) & JCVI GUIDELINES
PALIVIZUMAB RSV PROPHYLAXIS NHS ENGLAND AS PER SPECIFICATION AS PER SPECIFICATION √ √
RESPIRATORY SYNCYTIAL VIRUS PHE SPECIFICATION
PARA-AMINOSALICYLIC ACID NHS ENGLAND CLINICAL
MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
SPECIALIST ENDOCRINOLOGY
PARATHYROID HORMONE NHS ENGLAND PARATHYROID HORMONE AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
CONDITIONS
PARENTERAL NUTRITION (HOME
INTESTINAL FAILURE NHS ENGLAND PARENTERAL NUTRITION AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM AUDIT √ √
USE)
ONLY WHEN DURATION OF PN IS > 14

DAYS OR INITIATED PRIOR TO
PARENTERAL NUTRITION INTESTINAL FAILURE; INADEQUATE/
NHS ENGLAND PARENTERAL NUTRITION ADMISSION. ADULTS; SEE ALSO CG32. TRUST GUIDELINES TRUST GUIDELINES √
(INPATIENT USE) UNSAFE ENTERAL FEEDING
SEE ALSO 'MANUAL FOR PRESCRIBED
SPECIALISED SERVICES'

PARITAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
PASIREOTIDE ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NHS ENGLAND POLICY 16003/P
PASIREOTIDE CUSHING'S DISEASE NHS ENGLAND SOMATOSTATIN ANALOGUES NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
PAZOPANIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA215 NICE NICE SACT √
VIRAL HEPATITIS (B&C) & COMMISSIONING POLICY: B07/P/a; TA75,
PEG INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND NICE NICE NICE AUDIT √
RESPIRATORY SYNCYTIAL VIRUS TA96, TA106, TA200, TA 300
CG165
PEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ROUTINELY COMMISSIONED AS PER

PEGINTERFERON BETA-1A MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS SSC1534: MULTIPLE SCLEROSIS FIRST NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √****
LINE DISEASE MODIFYING AGENTS
PEGINTERFERON LAMBDA-1A HEPATITIS C NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPOTHALMIC & ANTERIOR
PEGVISOMANT ACROMEGALY NHS ENGLAND PITUITARY HORMONES & ANTI- NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
OESTROGENS
TA 357, TA366, TA428 NICE NICE
PEMBROLIZUMAB CANCER INDICATIONS NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF POLICY (TA 447) CDF CDF
PIRFENIDONE IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND PULMONARY FIBROSIS TA 504 (SPECIALIST CENTRE ONLY) NICE NICE NICE AUDIT √ √
DRUGS AFFECTING THE IMMUNE NUMBER OF PATIENTS
PLERIXAFOR STEM CELL MOBILISATION NHS ENGLAND COMMISSIONING POLICY: B04/P/b, NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RESPONSE SUCCESSFULLY TRANSPLANTED
16064/P
STAGE DRUG UTILISED
POMALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA427 NICE NICE SACT √ √
POMALIDOMIDE MYELOFIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PONATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA451 NICE NICE SACT √ √
DRUGS USED FOR NEUROMUSCULAR
PONESIMOD MULTIPLE SCLEROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
PRODUCT WITH LOWEST
PORACTANT ALFA RESPIRATORY DISTRESS SYNDROME NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

POSACONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
PRETOMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PRIVIGEN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
PROTEIN C NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
PROTHROMBIN COMPLEX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √
RALTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
GOUT AND CYTOTOXIC-INDUCED
RASBURICASE HYPERURICAEMIA NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
HYPERURICAEMIA
REGORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA488 NICE NICE SACT √ √
RESLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA479 NICE NICE NICE AUDIT √ √
LYSOSOMAL STORAGE DISORDER
REVEGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DRUGS
NHS ENGLAND CLINICAL NICE AUDIT
RIBAVIRIN HEPATITIS C NHS ENGLAND COMMISSIONING POLICY: B07/P/a; TA75, NICE NICE PRODUCT WITH LOWEST √
TA106, TA200 PROCUREMENT COST TO BE USED
RIGOSERTIB MDS/PANCREATIC CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CRYOPYRIN-ASSOCIATED PERIODIC
RILONACEPT NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SYNDROMES
RILPIVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
RIOCIGUAT NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERTENSION (CTEPH) COMMISSIONING POLICY: A11/P/c
HYPERTENSION
RIOCIGUAT NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
HYPERTENSION COMMISSIONING POLICY: 16055/P
HYPERTENSION
RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
STEROID SENSITIVE NEPHROTIC NHS ENGLAND CLINICAL
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
SYNDROME COMMISSIONING POLICY: E03/P/b
STEROID RESISTANT NEPHROTIC NHS ENGLAND CLINICAL
SYNDROME COMMISSIONING POLICY: E03/P/c
RITUXIMAB PRIMARY SJOGREN'S SYNDROME (PSS) NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
POLICY IN PROGRESS
CHRONIC INFLAMMATORY NOT ROUTINELY COMMISSIONED -
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DEMYELINATING POLYNEUROPATHY POLICY IN PROGRESS
RITUXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
RITUXIMAB ACQUIRED HAEMOPHILIA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
TA308 NICE/ NHS ENGLAND NICE/ NHS ENGLAND
RITUXIMAB ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NICE/ NHS ENGLAND POLICY √
NHS ENGLAND POLICY: A13/P/a POLICY POLICY
CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED -
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
INTERSTITIAL LUNG DISEASE POLICY IN PROGRESS
CYTOPENIA COMPLICATING PRIMARY NHS ENGLAND CLINICAL
IMMUNODEFICIENCY COMMISSIONING POLICY:16044/P
CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL
DISEASE COMMISSIONING POLICY:16069/P
RITUXIMAB SLE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY: A13/PS/a
RITUXIMAB MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY:16035/P
RITUXIMAB NEPHRITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RITUXIMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
ABO-INCOMPATIBLE KIDNEY
RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √
TRANSPLANTS
PEMPHIGUS VULGARIS AND NHS ENGLAND CLINICAL
PEMPHIGOID DISEASE COMMISSIONING POLICY:16035/P
RITUXIMAB IMMUNOGLOBIN G4 RELATED DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY:16057/P
TA65, TA137, TA174, TA193,
TA65, TA137, TA174, TA193,
TA65, TA137, TA174, TA193, TA226, TA243 TA226, TA243
RITUXIMAB IV CANCER NHS ENGLAND CYTOKINE MODULATORS TA226, TA243 SACT √
NHS ENGLAND CDF LETTER NHS ENGLAND CDF
NHS ENGLAND CDF LETTER
LETTER
AS PER CIRCULAR IE ONLY

RITUXIMAB SUBCUTANEOUS
CANCER NHS ENGLAND CYTOKINE MODULATORS COMMISSIONED FOR FOLLICULAR AS PER CIRCULAR AS PER CIRCULAR SACT √
FORMULATION
LYMPHOMA MAINTENANCE TREATMENT
ROMIPLOSTIM ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 221 NICE NICE NICE AUDIT √ √
ROPEGINTERFERON ALFA-2b HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ROXADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOLYTIC, AND RENAL ANAEMIAS
RUXOLITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 386 NICE NICE SACT √
SANDOGLOBULIN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
SAPROPTERIN CHILDREN WITH PHENYLKETONURIA NHS ENGLAND (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
COMMISSIONING POLICY: E06/P/a)
DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL
SAPROPTERIN MATERNAL PHENYLKETONURIA NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY HIGHLY SPECIALISED DATABASE √
DISORDERS COMMISSIONING POLICY: E12/P/a
SAQUINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
SARILUMAB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
DRUGS USED IN METABOLIC NOT ROUTINELY COMMISSIONED
SEBELIPASE ALFA LYSOSOMAL ACID LIPASE DEFICIENCY NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS NICE HST IN PROGRESS
SECUKINUMAB PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PULMONARY ARTERIAL NOT ROUTINELY COMMISSIONED
SELEXIPAG NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION NHS ENGLAND POLICY 160017/P
HYPERTENSION
SETROBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
SIALIC ACID MYOPATHY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
VASODILATOR ANTIHYPERTENSIVE AS PER POLICY

SILDENAFIL NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY PRODUCT WITH LOWEST √
HYPERTENSION PROCUREMENT COST TO BE USED
SIMEPREVIR/PEGINTERFERON + VIRAL HEPATITIS (B&C) &
HEPATITIS C NHS ENGLAND TA 331 NICE NICE HEPATITIS C MDS √ √
RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS

SIRUKUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
NARCOLEPSY - PEADIATRIC SERVICES NHS ENGLAND CLINICAL

SODIUM OXYBATE NHS ENGLAND HYPNOTICS & ANXIOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
ONLY COMMISSIONING POLICY: 16065/P
SODIUM PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
SOFOSBUVIR/DACLATASVIR + VIRAL HEPATITIS (B&C) &
SOFOSBUVIR/LEDIPASVIR +/- VIRAL HEPATITIS (B&C) &
SOFOSBUVIR/PEGINTERFERON+ VIRAL HEPATITIS (B&C) &
SOFOSBUVIR/VELPATASVIR HEPATITIS C NHS ENGLAND TA 430 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √
SORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 474 NICE NICE SACT √ √

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
STAVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
SUBCUVIA AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √

SUBGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
SUNITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA169, TA179, TA449 NICE NICE SACT √ √
SUSOCTOCOG ALFA (OBIZUR) HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TABALUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TADALAFIL NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √
HYPERTENSION
TAFAMANDIS AMYLOIDOSIS NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

TALIGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
TARIBAVIRIN HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TEDUGLUTIDE SHORT BOWEL SYNDROME NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TELAPREVIR HEPATITIS C NHS ENGLAND TA252 NICE NICE HEPATITIS C MDS √ √
VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED
TELBIVUDINE HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RESPIRATORY SYNCYTIAL VIRUS (TA154)
TEMSIROLIMUS CANCER CDF PROTEIN KINASE INHIBITORS CDF POLICY CDF CDF SACT √
RETROVIRAL DRUGS TA173 (FOR HEPATITIS B)/AGREED BHIVA GUIDELINES (8) BHIVA GUIDELINES (8)
TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS HARS DATASET √
HEPATITIS B +/- OTHER ANTI- REGIONAL GUIDELINES FOR HIV NICE NICE
RETROVIRAL DRUGS
TENOFOVIR ALAFENAMIDE HEPATITIS B NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TENOFOVIR ALAFENAMIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
TENOFOVIR ALAFENAMIDE +
COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
EMTRICITABINE (GENVOYA®)
TENOFOVIR DISOPROXIL + NHS ENGLAND CLINICAL
COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √
RETROVIRAL DRUGS
EMTRICITABINE (STRIBILD®) F03/P/b/AGREED REGIONAL GUIDELINES
TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI-
EFAVIRENZ RETROVIRAL DRUGS
TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI-
RILPIVIRINE RETROVIRAL DRUGS
TA303
TERIFLUNOMIDE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NICE NICE NICE AUDIT √ √****
DRUGS AFFECTING BONE NOT ROUTINELY COMMISSIONED
TERIPARATIDE OSTEOGENESIS IMPERFECTA NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM NHS ENGLAND POLICY: 16002/P
DRUGS AFFECTING BONE
TERIPARATIDE MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
TETRAHYDROBIOPTERIN PHENYLKETONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
TEZACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
THALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA228 NICE NICE SACT √
THROMBIN PSEUDOANEURYSM NHS ENGLAND BLOOD-RELATED PRODUCTS IPG060 IPG060 NICE √

TIPRANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
TOBRAMYCIN CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √*
TA276
TOCILIZUMAB IV JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY: E03/P/d; TA NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √
373
TOCILIZUMAB TAKAYASU ARTERITIS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
COMMISSIONING POLICY 16056/P
NOT ROUTINELY COMMISSIONED NHS
TOCILIZUMAB GIANT CELL ARTERITIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TOCILIZUMAB IV NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA'S (TA247 and TA375) NICE NICE NICE AUDIT √
ADULT TA AVAILABLE)
TOFACITINIB NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ADULT TA AVAILABLE)
POSTERIOR PITUITARY HORMONES NHS ENGLAND CLINICAL
TOLVAPTAN HYPONATRAEMIA IN CANCER NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √
AND ANTAGONISTS COMMISSIONING POLICY 16051/P
TRALOKINUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TRENONACOG ALPHA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
PULMONARY ARTERIAL
TREPROSTINIL DIETHANOLAMINE NHS ENGLAND DRUGS/PULMANORY ARTERIAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION
HYPERTENSION
NOT ROUTINELY COMMISSIONED FOR
PULMONARY ARTERIAL NEW PATIENTS - NHS ENGLAND
TREPROSTINIL SODIUM NHS ENGLAND DRUGS/PULMANORY ARTERIAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HYPERTENSION CLINICAL COMMISSIONING POLICY:
HYPERTENSION
A11/P/c
TRIENTENE WILSONS DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
DISORDERS
TUROCTOCOG ALFA (NovoEight) NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES √
PAEDIATRIC INDICATIONS (OR WHERE DRUGS AFFECTING IMMUNE AS PER TA455 AND ADULT TA's (TA180,
USTEKINUMAB NHS ENGLAND NICE NICE NICE √ √
ADULT TA AVAILABLE) RESPONSE TA340)

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL

VADADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
HAEMOLYTIC, AND RENAL ANAEMIAS

VALGANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
SACT
VANDETANIB THYROID CANCER CDF PROTEIN KINASE INHIBITORS CDF POLICY CDF CDF √
CDF NATIONAL AUDIT
VEDOLIZUMAB NHS ENGLAND CYTOKINE MODULATORS AS PER ADULT TA's (TA 342, TA 352) NICE NICE NICE AUDIT √ √
ADULT TA AVAILABLE)

VELAGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √
DRUGS AFFECTING BONE

VELCALCETIDE HYPERPARATHYROIDISM NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
METABOLISM
VEMURAFENIB MELANOMA NHS ENGLAND PROTEIN KINASE INHIBITORS TA269 NICE NICE NICE AUDIT √
VIGAM AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
VIVAGLOBIN AS PER NATIONAL DMP NHS ENGLAND IMMUNOGLOBULIN USE, SECOND NATIONAL GUIDELINES NATIONAL GUIDELINES QUALITY DASHBOARD √
VON WILLEBRAND FACTOR,
VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RECOMBINANT
VORICONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √
CHRONIC PULMONARY HIGHLY SPECIALISED HIGHLY SPECIALISED
VORICONAZOLE NHS ENGLAND ANTIFUNGALS HIGHLY SPECIALISED CRITERIA ONLY √
ASPERGILLOSIS CRITERIA ONLY CRITERIA ONLY
NOT ROUTINELY COMMISSIONED - NHS
ZICONOTIDE INTRATHECAL ANALGESIA NHS ENGLAND NON-OPIOID ANALGESICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
ZIDOVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ZIDOVUDINE + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √
RETROVIRAL DRUGS
ZIDOVUDINE + LAMIVUDINE + HIV IN COMBINATION WITH OTHER ANTI-
ABACAVIR RETROVIRAL DRUGS
OTHER DRUGS NOT LISTED
UNDER PBR EXCLUSIONS
LAMBERT EATON MYASTHENIC
3,4 DIAMINOPYRIDINE NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
SYNDROME
AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER CDIFR APPROVAL AS PER CDIFR APPROVAL SACT √
TREATMENT OF BREAST CANCER
ALBUMIN BOUND PACLITAXEL PATIENTS WITH DOCUMENTED NHS ENGLAND CANCER EXCLUSION TA 476 NICE NICE SACT √ √
TAXANE HYPERSENSITIVITY
ATEZOLIZUMAB CANCER CDF CANCER EXCLUSION CDF (TA 492) CDF CDF SACT √ √
AUTOLOGOUS CHONDROCYTE
ARTICULAR CARTILAGE DEFECT NHS ENGLAND TA 477 NICE NICE NICE AUDIT √
IMPLANTATION
TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL
AZATHIOPRINE NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √*
ONLY REPATRIATION AGREED
NHS ENGLAND/ TA216 NICE NICE
BENDAMUSTINE CANCER CANCER EXCLUSION SACT √
BLINATUMOMAB CANCER NHS ENGLAND CANCER EXCLUSION TA450 NICE NICE SACT √ √
NHS ENGLAND/ TA446, TA478 NICE NICE
BRENTUXIMAB CANCER CANCER EXCLUSION SACT √ √
CABAZITAXEL CANCER NHS ENGLAND CANCER EXCLUSION TA 391 NICE NICE SACT √ √
TA 463 NICE NICE
CABOZANTINIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF POLICY CDF CDF
CARFILZOMIB CANCER NHS ENGLAND CANCER EXCLUSION TA 457 NICE NICE SACT √ √
CERITINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 395, TA 500 NICE NICE SACT √ √
NHS ENGLAND/ TRUST GUIDELINES/ NICE/ TRUST GUIDELINES/ NICE/
CHEMOTHERAPY CANCER - (NOT SPECIFICALLY LISTED) CANCER EXCLUSION TRUST GUIDELINES/ NICE/ CDF POLICY SACT √
CDF CDF POLICY CDF POLICY
TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL PRODUCT WITH LOWEST
CICLOSPORIN NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √*
ONLY REPATRIATION AGREED PROCUREMENT COST TO BE USED
HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE
CINACALCET NHS ENGLAND TA117 NICE NICE √
PATIENTS ONLY DISORDERS
CLOFARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √
DRUGS FOR MINERAL BONE
COLESTILAN ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
DARATUMUMAB CANCER CDF CANCER EXCLUSION CDF (TA 510) CDF CDF SACT √
RENAL DIALYSIS ONLY, INCLUDING VIA
PRODUCT WITH LOWEST
DARBEPOETIN DIALYSIS-INDUCED ANAEMIA NHS ENGLAND ERYTHROPOETINS OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES TRUST GUIDELINES √
CG114
RENAL DIALYSIS ONLY, INCLUDING VIA NICE NICE PRODUCT WITH LOWEST
EPOETIN (ALL VARIANTS) DIALYSIS-INDUCED ANAEMIA NHS ENGLAND ERYTHROPOETINS OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES (RENAL TRUST GUIDELINES (RENAL PROCUREMENT COST TO BE USED √
CG114 USE ONLY) USE ONLY) (NICE CG114)
NHS ENGLAND/ NICE TA 423 NICE NICE
ERIBULIN CANCER CANCER EXCLUSION SACT √
HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE
ETELCALCETIDE NHS ENGLAND TA448 NICE NICE √ √
PATIENTS ONLY DISORDERS
FACTOR X (COAGADEX) HEREDITARY FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
TA429 NICE NICE
IBRUTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORS SACT √ √
CDF (TA491) CDF CDF
IDELALISIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 359 NICE NICE SACT √
IPILIMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA268, TA319, 400 NICE NICE SACT √
LANTHANUM ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
LENVATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA498 NICE NICE SACT √ √
MESENCHYMAL STEM CELLS (E.G. ACUTE GVHD AND OTHER
PROCHYMAL®) INDICATIONS (BCSH)

SUITABLE FOR
SUITABLE FOR
SHARED CARE
BETWEEN
SPECIALIST
SECONDARY
CARE VIA
NETWORK
COMMITTEE)
MODEL
TA481, TA482
TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST
MYCOPHENOLATE MOFETIL NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
ONLY PROCUREMENT COST TO BE USED
REPATRIATION AGREED
TA481, TA482
MYCOPHENOLIC ACID NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
REPATRIATION AGREED
NELARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √
TA 384, 400, 417, 462 NICE NICE
NIVOLUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF (TA 483, TA 484, TA 490) CDF CDF
TA343 & 513 NICE NICE
OBINUTUZUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √
CDF (TA472) CDF CDF
OLAPARIB CANCER NHS ENGLAND CANCER EXCLUSION TA 381 NICE NICE SACT √
OLARATUMAB CANCER CDF CANCER EXCLUSION CDF (TA 465) CDF CDF SACT √ √
OSIMERTINIB CANCER CDF CANCER EXCLUSION CDF (TA 416) CDF CDF SACT √
PALBOCICLIB CANCER NHS ENGLAND CANCER EXCLUSION TA 495 NICE NICE SACT √ √
PANITUMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA439 NICE NICE SACT √ √
PANOBINOSTAT CANCER NHS ENGLAND CANCER EXCLUSION TA 380 NICE NICE SACT √
PEGASPARGASE CANCER NHS ENGLAND CANCER EXCLUSION TA 408 NICE NICE SACT √
PEGYLATED LIPOSOMAL NHS ENGLAND/ TA91 NICE NICE

CANCER CANCER EXCLUSION SACT √
DOXORUBICIN CDF CDF POLICY CDF CDF
NHS ENGLAND/ TA135, TA181, TA190, TA 402 NICE NICE
PEMETREXED CANCER CANCER EXCLUSION SACT √
CDF CDF CDF
PEPTIDE RECEPTOR
CANCER CDF NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
RADIONUCLEOTIDE THERAPY
PERTUZUMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 424 & 509 NICE NICE SACT √ √
PIXANTRONE CANCER NHS ENGLAND CANCER EXCLUSION TA306 NICE NICE SACT √
ENDOCRINOLOGY; NON-MALIGNANT
PROTEIN KINASE INHIBITORS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CONDITIONS
NHS ENGLAND/ NICE NICE
RADIUM-223 DICHLORIDE CANCER CANCER EXCLUSION NICE TA 376, TA 412 SACT √
CDF CDF CDF
RAMUCIRUMAB CANCER NHS ENGLAND CANCER EXCLUSION CDIFR CDIFR AS PER IFR APPROVAL √
TA 378
RIBOCICLIB CANCER NHS ENGLAND CANCER EXCLUSION TA 496 NICE NICE SACT √ √
SEVELAMER ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √
DISORDERS
TA481, TA482
SIROLIMUS (RAPAMUNE) NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
REPATRIATION AGREED
ADENOSINE DEAMINASE DEFICIENCY-
STRIMVELIS SEVERE COMBINED NHS ENGLAND ATMP HST7 NICE NICE NICE AUDIT √
IMMUNODEFICIENCY
CONTROL OF SERUM PHOSPHORUS
SUCROFERRIC OXYHDROXIDE NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √
LEVELS IN DIALYSIS PATIENTS
TA481, TA482
TACROLIMUS NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √*
REPATRIATION AGREED
TALIMOGENE LAHERPAREPVEC CANCER NHS ENGLAND CANCER EXCLUSION TA 410 NICE NICE SACT √
ENDOCRINOLOGY; NON-MALIGNANT
TEMOZOLOMIDE NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √
CONDITIONS
TIVOZANIB CANCER CDF CANCER EXCLUSION TA 512 CDF CDF SACT √ √
TRABECTEDIN CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA185 NICE NICE SACT √
TRAMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 396 NICE NICE SACT √ √
TRASTUZUMAB CANCER NHSE ENGLAND CANCER EXCLUSION TA 34, 107, 208 NICE NICE SACT √
TRASTUZUMAB EMTANSINE CANCER NHS ENGLAND CANCER EXCLUSION TA 458 NICE NICE SACT √ √
TRIFLURIDINE–TIPIRACIL CANCER NHS ENGLAND CANCER EXCLUSION TA 405 NICE NICE SACT √
VENETOCLAX CANCER CDF CANCER EXCLUSION CDF (TA 487) CDF CDF SACT √ √
* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT
** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED
*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE

**** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT
NEW LINES ADDED TO V13 LIST

CHANGES TO V12 17/18 LIST
ADDITIONAL NOTES:
1. WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE
2. CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN NON CANCEROUS HAEMOTOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA)
3. ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILTY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS
ENGLAND RESPONSIBILITY)
4. IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF
5. USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - CCG's ARE RESPONSIBLE FOR ALL OTHER INDICATIONS
6. NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE
7. NHS ENGLAND COMMISSIONS ARVS AS PER PUBLISHED POLICIES, FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO
8.DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN. A PRESCRIBING POLICY IS IN
DEVELOPMENT TO CLARIFY THESE ARRANGEMENTS”. THIS WILL APPLY TO ANY DRUG WHERE WE HAVE STATED “AS PER ADULT TA” AS THE TA/ POLICY. A PRIOR APPROVAL SYSTEM WILL BE IMPLEMENTED ALONG SIDE THE POLICY.
9. CINACALCET FOR COMPLEX PRIMARY PARATHYROIDISM IS IN TARIFF

Nhs England Drugs List v13

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Nhs England Drugs List v13

Hochgeladen von

Copyright:

Verfügbare Formate

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND

VERSION 13 PUBLISHED APRIL 2018

HIGHLY SPECIALISED HIGHLY SPECIALISED

NUMBER OF PATIENTS TREATED

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 1 23/03/2018

APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC,

HIV IN COMBINATION WITH OTHER ANTI-

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 2 23/03/2018

CONGENITAL FACTOR XIII A-SUBUNIT

NHS ENGLAND CLINICAL

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 3 23/03/2018

NHS ENGLAND CLINICAL

NHS NATIONAL SPECIALISED

VIRAL HEPATITIS (B&C) &

HIV IN COMBINATION WITH OTHER ANTI-

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 4 23/03/2018

TREATMENT OF ADULT PATIENTS WITH

AS PER BCSH GUIDELINES FOR

VIRAL HEPATITIS (B&C) &

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 5 23/03/2018

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 6 23/03/2018

GROWTH HORMONE & GROWTH

PRODUCT WITH LOWEST

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 7 23/03/2018

ONLY WHEN DURATION OF PN IS > 14

VIRAL HEPATITIS (B&C) &

ROUTINELY COMMISSIONED AS PER

NUMBER OF PATIENTS TREATED

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 8 23/03/2018

AS PER CIRCULAR IE ONLY

VASODILATOR ANTIHYPERTENSIVE AS PER POLICY

PAEDIATRIC INDICATIONS (WHERE DRUGS AFFECTING THE IMMUNE

NARCOLEPSY - PEADIATRIC SERVICES NHS ENGLAND CLINICAL

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 9 23/03/2018

CLINICAL GUIDELINES FOR

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

THROMBIN PSEUDOANEURYSM NHS ENGLAND BLOOD-RELATED PRODUCTS IPG060 IPG060 NICE √

HIV IN COMBINATION WITH OTHER ANTI-

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 10 23/03/2018

DRUGS USED IN HYPOPLASTIC,

NUMBER OF PATIENTS TREATED

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED

DRUGS AFFECTING BONE

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 11 23/03/2018

PEGYLATED LIPOSOMAL NHS ENGLAND/ TA91 NICE NICE

** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED

*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE

NEW LINES ADDED TO V13 LIST

NHS England drugs-list v13 NHSE Commissioned PbRE Drugv13 12 23/03/2018

Das könnte Ihnen auch gefallen